Zenagamtide
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. In the United States, most of these compounds are not FDA-approved and are sold for laboratory research only; a few are prescription drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
No established human dose — this compound doesn't have a settled protocol yet.
Amycretin is a unimolecular GLP-1/amylin receptor agonist from Novo Nordisk, available in both injectable and oral forms. Early phase 1b/2a data showed up to ~24% weight loss at 36 weeks with the subcutaneous form and ~13% at 12 weeks orally, but these are small, early trials and phase 3 is only planned. It is beginning to appear on research-vendor catalogs on the strength of those headline numbers.
